SUBSCRIBE
SUBSCRIBE

Phase 3

Drug Development
3 Of The Most Promising Diabetes Meds From 5 Of The Most Innovative Biotechs In The World
March 27, 2017
 · 
1 min read
Drug Development
Breaking The Cold Chain: New Vaccine Doesn’t Need Refrigeration
March 23, 2017
 · 
1 min read
3 Biotechs That Could be Taken Out This Quarter
Drug Development
5 Biotechs That Have Major Catalysts Coming in the Next 6 to 9 Months
March 22, 2017
 · 
3 min read
How Eli Lilly Allegedly Used a Fake Rule and Fake News to Protect Bad Patents
Drug Development
Investors Squeal With Delight as Eli Lilly’s Breast Cancer Combo Succeeds in Phase III, Faces Tough Competition from Pfizer and Novartis AG
March 20, 2017
 · 
3 min read
Bay Area's Nektar Inks $400 Million+ Autoimmune Disease Pact With Eli Lilly
Drug Development
For Sale: Nektar Therapeutics Plans to License Hot New Opioid Drug
March 20, 2017
 · 
3 min read
Why This Tiny Biotech is Giving Cash to Amgen Researchers
Drug Development
Disappointment Hits as Amgen’s Repatha Prevents Heart Attacks, But Not Deaths
March 17, 2017
 · 
4 min read
Pharma Giant AstraZeneca PLC Scores Another FDA Breakthrough
Drug Development
AstraZeneca PLC Steals Tesaro’s PARP Thunder With Phase III Ovarian Cancer Data
March 15, 2017
 · 
2 min read
Roche Slammed With Partial Holds for Two Combo Cancer Trials
Drug Development
One Death in the HAVEN 1 Trial Complicates Roche’s Entry into the Hemophilia A Market
March 13, 2017
 · 
4 min read
Drug Development
Investors Anxiously Await for Amgen’s 27,500-Patient Heart Trial Data This Week
March 13, 2017
 · 
1 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
Drug Development
FDA Demands Karyopharm Stop Enrollment of All Selinexor Trials
March 13, 2017
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites
February 2, 2026
 · 
2 min read
Press Releases
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
February 2, 2026
 · 
4 min read
Press Releases
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 2, 2026
 · 
8 min read
Press Releases
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
February 2, 2026
 · 
14 min read
Press Releases
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
February 2, 2026
 · 
11 min read
Press Releases
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit
February 1, 2026
 · 
12 min read
Press Releases
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
February 1, 2026
 · 
12 min read
Press Releases
Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
January 30, 2026
 · 
9 min read
Press Releases
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
January 30, 2026
 · 
6 min read
Press Releases
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
January 29, 2026
 · 
7 min read
Press Releases
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
January 29, 2026
 · 
3 min read
Press Releases
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
January 29, 2026
 · 
2 min read
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
 · 
8 min read
Press Releases
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
January 29, 2026
 · 
6 min read
Press Releases
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 29, 2026
 · 
4 min read
Press Releases
OKYO Pharma Announces Successful Type C Meeting with the FDA
January 29, 2026
 · 
5 min read
Press Releases
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
January 28, 2026
 · 
3 min read
Press Releases
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
January 28, 2026
 · 
4 min read
Press Releases
Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
January 28, 2026
 · 
7 min read
Press Releases
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
January 28, 2026
 · 
6 min read
Load More